论文部分内容阅读
目的 :观察胸腺肽α1 联合促肝细胞生长素 (HGF)治疗慢性重症肝炎的疗效。方法 :慢性重症肝炎 6 4例 ,分成治疗组 2 4例 ,对照组 4 0例。对照组用 HGF等支持、保肝疗法 ;治疗组在此基础上加胸腺肽α1 ,观察疗效及病死率 ,3个月后检测血清总胆红素、谷丙转氨酶、凝血酶原时间、透明质酸等水平。结果 :治疗组总有效率为 75 .4 % ,病死率为 2 5 .0 % ;对照组总有效率为 4 5 .0 % ,病死率为 4 7.5 % ,两组比较差异有显著性意义 (P <0 .0 5 ) ;治疗组与对照组治疗前各项生化指标比较差异无显著性意义 (P >0 .0 5 ) ,治疗后两组生化指标均有所下降 ,两组比较差异有非常显著性意义 (P <0 .0 1)。结论 :胸腺肽α1 联合 HGF能显著减轻肝脏的损伤程度 ,降低病死率 ,而且患者耐受性好 ,无不良反应
Objective: To observe the efficacy of thymosin α1 combined with hepatocyte growth-promoting hormone (HGF) in the treatment of chronic severe hepatitis. Methods: Sixty-four cases of chronic severe hepatitis were divided into treatment group (24 cases) and control group (40 cases). Control group with HGF and other support, liver therapy; the treatment group on the basis of thymosin α1, to observe the efficacy and mortality, after 3 months of serum total bilirubin, alanine aminotransferase, prothrombin time, hyaluronic acid And so on. Results: The total effective rate was 75.4% in the treatment group and the mortality rate was 25.0%. The total effective rate in the control group was 45.0% and the mortality rate was 47.5%. There was significant difference between the two groups P <0.05). There was no significant difference in each biochemical index between the treatment group and the control group before treatment (P> 0.05). The biochemical indexes decreased after treatment in both groups Very significant (P <0.01). Conclusion: Thymosin α1 combined with HGF can significantly reduce the degree of liver damage, reduce mortality, and patients with good tolerance, no adverse reactions